CN108210454A - A kind of Orally taken emulsion of Pabuk former times profit cloth and preparation method thereof - Google Patents
A kind of Orally taken emulsion of Pabuk former times profit cloth and preparation method thereof Download PDFInfo
- Publication number
- CN108210454A CN108210454A CN201611152864.0A CN201611152864A CN108210454A CN 108210454 A CN108210454 A CN 108210454A CN 201611152864 A CN201611152864 A CN 201611152864A CN 108210454 A CN108210454 A CN 108210454A
- Authority
- CN
- China
- Prior art keywords
- former times
- acid
- pabuk former
- times profit
- profit cloth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Abstract
The invention belongs to pharmaceutical fields, and in particular to a kind of Orally taken emulsion of Pabuk former times profit cloth and preparation method thereof.The Orally taken emulsion includes the Pabuk former times profit cloth free alkali or its officinal salt, 0.1~5% acceptable acidic auxiliary material, 0.1~5% sweetener, 0.01~0.5% antioxidant, 0.1~10% medicinal oil and 1~10% medicinal emulsifier that mass ratio is 0.1~1%.Compared with conventional formulation, the present invention has more excellent oral absorption property, available for reducing the oral absorption difference of Pabuk former times profit cloth and improving bioavilability.
Description
Technical field
The invention belongs to pharmaceutical fields.More particularly it relates to a kind of Pabuk former times profit cloth (palbociclib, again
Claim that pa wins XiLin, pa wins former times cloth, Pa Boxini, pa Berkeley etc.) Orally taken emulsion and preparation method thereof.The Pabuk former times of the present invention
Sharp cloth can be Pabuk former times profit cloth free alkali or its any officinal salt.
Background technology
World Health Organization's statistical data shows that breast cancer is to lead to women in worldwide because in the cancer mortality cause of disease
The second killer.In the past few decades, the incidence of breast cancer shows a rising trend.The year two thousand twenty is expected, annual breast cancer is new
Example of falling ill will be more than 1,700,000.There are 1,670,000 breast cancer new cases in worldwides in 2012, account for all cancers and newly send out
The 25% of case.Wherein developed country has 88.3 ten thousand；Developing country has 79.4 ten thousand.The breast cancer of developing country is newly sent out
Case growth rate is slightly above developed country.Because the case of breast cancer deaths is 52.2 ten thousand, the lethality position in all cancers
Arrange the 5th；It is 32.4 ten thousand to cause women die number in low developed area, accounts for 14.3% in all cases because of cancer mortality, is
Most frequent lethal cancer；In the women of developed regions, because the death of breast cancer is 19.8 ten thousand, account for all because cancer is dead
The 15.4% of case is died, is only second to lung cancer.Therefore, breast cancer is still one of global important health problem.
According to international application published WO2003/062236, Pabuk former times profit cloth is that a kind of cyclin dependent swashs
The inhibition drug of enzyme (CDK) 4 and 6 mainly prevents cell by the G1 phases to S phases and then inhibition DNA by inhibiting CDK4/6 activity
Synthesis, available for treating metastatic breast cancer.Clinical experimental study finds that Pabuk former times profit cloth combines Letrozole to postclimacteric
Local infiltration patient with breast cancer or the estrogen receptor (ER) diagnosed recently are positive, and the patient of HER-2 feminine genders is highly effective.Pa
Its chemical constitution of cloth former times profit cloth is shown below：
The structure and preparation method of this compound and its salt are special in international application published WO2003/062236 and the U.S.
It is had been described in profit application No.6,936,612.In international application published WO2005/005426 and U.S. Patent application
The preparation method of the salt of free alkali and various acid is also illustrated in Nos.7,345,171 and 7,863,278.
Pabuk former times profit cloth was ratified to list in 2015 in the U.S., according to the introduction of the FDA specifications announced, Pabuk former times
The solubility of sharp cloth free alkali in water is very big with pH value influence, and when pH is equal to or less than 4, Pabuk former times profit cloth has higher
Dissolubility, but when pH is more than 4, the water solubility of Pabuk former times profit cloth reduces rapidly.Low-solubility is unfavorable for drug and is inhaled by human body
It receives, causes bioavilability low.If by the way that Pabuk former times profit cloth free alkali is reacted into salt to increase solubility with acid, according to it
Preceding existing patent report, the solid state properties of salt are bad, are unfavorable for exploitation into solid pharmaceutical preparation.
In addition, found in the clinical test of Pabuk former times profit cloth, it is widely different after different patient's oral absorptions, about 13%
Patient absorbs very poor upon administration.For these patients, the drug effect of this product can be than relatively low, this is likely due to the drug
Indissoluble property cause it is poor in some patients' body absorption.Thus, the dosage form of Pabuk former times profit cloth is further improved, so as to
Increase its dissolution rate and bioavilability, be very necessary from present's view.
In addition, clinical test results also found, food has higher influence to the oral absorption of Pabuk former times profit cloth.After meal
Medication can significantly improve absorption, wherein high hot food high in fat can improve 21%, low fat and low heat food can improve 12%.This also may be used
One of the reason of being absorption difference of the different patients to this medicine.
For this purpose, the new formulation of urgent clinical needs Pabuk former times profit cloth, can realize higher oral absorption, and not by diet
It influences, reduces the drug effect difference of patient.
Summary of the invention
The purpose of the present invention is developing a kind of pharmaceutical preparations product, the bio-absorbable of Pabuk former times profit cloth is improved, is reduced clinical
Individual absorption difference.
It is an unexpected discovery of the invention that although document report Pabuk former times profit cloth can increase sharply in aqueous solutions of the pH less than 4
Its solubility, however in the buffer solution composition of different pH, dissolubility is widely different, as shown in table 1, in chloride ion-containing and phosphoric acid
In the buffer solution of radical ion, Pabuk former times profit cloth is reduced rapidly with the increase of its molar concentration, solubility.On the contrary, with pharmaceutically
Acceptable organic acidity auxiliary material can't influence its changes in solubility trend.
Inconvenience is taken to what patient brought in view of relatively low pH aqueous solutions, appropriate corrigent should be added in alleviate acid
Taste.Although the oral aqueous solution that Pabuk former times profit cloth is prepared into low ph value realizes higher gastrointestinal tract exposed amount, can not change
Become absorption individual difference of the diet to the medicine, therefore the appropriate lubricant component that increases will preferably be selected.
Present invention discover that dissolubility of the Pabuk former times profit cloth in common grease is bad, as shown in table 2, except being slightly soluble in oleic acid
Outside linoleic acid, equal slightly soluble or atomic molten in other greases, thus it is speculated that it may be because bile emulsifies to be absorbed caused by high fat diet
The reason of.In view of its larger dissolubility in acidic aqueous solution, if Pabuk former times profit cloth bulk pharmaceutical chemicals added in a small amount of acid
After auxiliary material aqueous solution, Orally taken emulsion is made in the pharmaceutically acceptable grease of reselection and emulsifier, then can greatly increase Pabuk
The drugloading rate of former times profit cloth.The Orally taken emulsion can improve the gastrointestinal absorption of Pabuk former times profit cloth and the diet of reduction patient is brought
Absorption difference.
Specifically, the present invention provides a kind of Orally taken emulsion of Pabuk former times profit cloth, it is 0.1~1% including mass ratio
Pabuk former times profit cloth free alkali or its officinal salt, 0.1~5% acceptable acidic auxiliary material, 0.1~5% sweetener, 0.01~
0.5% antioxidant, 0.1~10% medicinal oil and 1~10% medicinal emulsifier.
Heretofore described acceptable acidic auxiliary material is selected from acetic acid, tartaric acid, fumaric acid, succinic acid, citric acid, apple
Acid, aliphatic sulfonic and aromatic sulphonic acid, preferably tartaric acid.
Heretofore described aliphatic sulfonic is selected from methanesulfonic acid, ethanesulfonic acid and isethionic acid.
Heretofore described aromatic sulphonic acid is selected from benzene sulfonic acid and p-methyl benzenesulfonic acid.
Heretofore described sweetener is selected from natural sweetener or synthetic sweetener.
Heretofore described sweetener is selected from sucrose, steviol glycoside, saccharin sodium, aspartame, Sucralose or its group
It closes.
Heretofore described antioxidant is selected from vitamin E, butylated hydroxytoluene or butylated hydroxy anisole.
Heretofore described medicinal oil is selected from refined plant oil, including oleic acid, linoleic acid, peanut oil, soybean oil, corn
Oil, coconut oil, isopropyl myristate, Glycerin, mixed triester with caprylic acid capric acid or combination.
Heretofore described medicinal emulsifier is selected from the common emulsifier for taking orally of the art, including moon silicon
- 32 glyceride of acid polyethylene glycol, sad LABRAFIL M 1944CS, Labraso, Tweens surface-active
Agent, Emulsifier EL-60, Crodaret and polyethylene glycol 15 hydroxystearate or combination.
Heretofore described Orally taken emulsion further includes the common medicinal organic solvent of the art, selected from ethylene glycol,
Propylene glycol, isopropanol, Solutol HS15, ethylene glycol monomethyl ether, diethylene glycol ether and polyethylene glycol
300~600 or combinations.
Heretofore described Orally taken emulsion further includes the common preservative of the art, selected from benzoic acid, nipalgin
Ester, sorbic acid or combination etc..
Heretofore described Orally taken emulsion, it is characterised in that the pH of emulsion is less than 4.
Heretofore described Orally taken emulsion, preferably dosage 10mg-200mg, 50-150mg.
The preparation method of heretofore described Orally taken emulsion, it is characterised in that include the following steps：
(1) prepare raw material according to aforementioned proportion；
(2) aqueous solution of acidic excipient is prepared；
(3) it is added in Pabuk former times profit cloth free alkali or its officinal salt in oxytropism auxiliary material aqueous solution, until dissolving is complete；
(4) sweetener, medicinal organic reagent and preservative are added in into more than aqueous solution, dissolving is complete；
(5) medicinal emulsifier is added in into medicinal oil, until dissolving is complete；
(6) Jiang Shui, oil two kinds of solution mixing by quickly stirring or ultrasound, obtain the emulsion of stable and uniform.
Heretofore described Orally taken emulsion is used to treat breast cancer.
Brief description
In order to more clearly describe technical scheme of the present invention, briefly introduce below in conjunction with attached drawing.It is clear that this
A little attached drawings are only some specific embodiments that the application records.The present invention includes but not limited to these attached drawings.
Fig. 1 shows the In Vitro Dissolution curve of one preparation of the embodiment of the present invention；And
Fig. 2 shows the In Vitro Dissolution curves of two preparation of the embodiment of the present invention.
Specific embodiment
For a further understanding of the present invention, the preferred embodiment of the present invention is described below in conjunction with embodiment.These
Description is merely illustrative the feature and advantage of new medicinal preparation of the present invention, the protection domain being not intended to limit the present invention.
Embodiment 1
(1) it weighs tartaric acid 150mg to be dissolved in 20mL purified waters, stirring and dissolving is complete, obtains clear transparent solutions；
(2) it weighs Pabuk former times profit cloth free alkali 125mg and adds in prepared aqueous tartaric acid solution in previous step, stirring is complete to dissolving；
(3) 100mg Sucraloses, 5mL Labrasos, 4.75mL polyethylene glycol 400s are added in into above-mentioned solution
With 20mg sodium benzoates, stirring makes it completely dissolved；(4) 0.6g corn oils, 20mg fourth hydroxyls are added in into above-mentioned aqueous solution
Toluene and 20mg butylated hydroxy anisoles, stirred under the rotating speed of 1000rpm by high speed agitator 10min to get.
Embodiment 2
(1) 100mg citric acids are weighed and 100mg tartaric acid is dissolved in 20mL purified waters, stirring and dissolving is complete, obtains clear
Clear clear solution；(2) it weighs Pabuk former times profit cloth free alkali 125mg and adds in prepared citric acid and tartaric acid mixing in previous step
Aqueous solution, stirring are complete to dissolving；(3) it is sweet that 100mg aspartames, 9mL caprylic capric polyethylene glycol are added in into above-mentioned solution
Grease, 2mL polyethylene glycol 400s and 20mg sodium benzoates, stirring make it completely dissolved；(4) 1.5g is added in into above-mentioned aqueous solution
Coconut oil and 40mg vitamin Es, stirred under the rotating speed of 1000rpm by high speed agitator 10min to get.
Embodiment 3
(1) it weighs malic acid 100mg to be dissolved in 20mL purified waters, stirring and dissolving is complete, obtains clear transparent solutions；
(2) it weighs Pabuk former times profit cloth free alkali 75mg and adds in prepared aqueous solution of malic acid in previous step, stirring is complete to dissolving；
(3) 150mg saccharin sodiums, 5mL Emulsifier EL-60s, 4.75mL polyethylene glycol 400s and 10mg benzene first are added in into above-mentioned solution
Sour sodium, stirring make it completely dissolved；(4) 0.1g oleic acid and 40mg vitamin Es are added in into above-mentioned aqueous solution, by high-speed stirred
Device stirred under the rotating speed of 1000rpm 10min to get.
The following table 1 and table 2 respectively illustrate solubility of the Pabuk former times profit cloth in the aqueous solution and different greases of different pH.
Solubility of the 1. Pabuk former times profit cloth free alkali of table in different buffer solvents
Solubility of the table 2.20mg Pabuk former times profit cloth free alkalis in different medicinal oils
The In Vitro Dissolution curve that 1 preparation of the embodiment of the present invention and 2 preparation of embodiment are measured by common method shows respectively
In Fig. 1 and Fig. 2.
The explanation of above example is only intended to help to understand core concept of the invention.It should be pointed out that for this field
Those of ordinary skill for, without departing from the principle of the present invention, can also to the present invention new formulation and its system
Some improvement and modification can also be carried out for Preparation Method, but these improvement and modification also fall into the claimed range of the claims in the present invention
It is interior.
Claims (16)
1. a kind of Orally taken emulsion of Pabuk former times profit cloth, including the Pabuk former times profit cloth free alkali that mass ratio is 0.1~1% or its can
Pharmaceutical salts, 0.1~5% acceptable acidic auxiliary material, 0.1~5% sweetener, 0.01~0.5% antioxidant, 0.1~
10% medicinal oil and 1~10% medicinal emulsifier.
2. the Orally taken emulsion of Pabuk former times profit cloth according to claim 1, it is characterised in that the pH of emulsion is less than 4.
3. the Orally taken emulsion of Pabuk former times profit cloth according to claim 1, it is characterised in that the pH of emulsion is less than 3.
4. the Orally taken emulsion of Pabuk former times profit cloth according to claim 1, wherein the acceptable acidic auxiliary material be selected from acetic acid,
Tartaric acid, fumaric acid, succinic acid, citric acid, malic acid, aliphatic sulfonic and aromatic sulphonic acid.
5. the Orally taken emulsion of Pabuk former times profit cloth according to claim 4, wherein the aliphatic sulfonic is selected from methanesulfonic acid, second
Sulfonic acid and isethionic acid.
6. the Orally taken emulsion of Pabuk former times profit cloth according to claim 4, wherein the aromatic sulphonic acid be selected from benzene sulfonic acid and
P-methyl benzenesulfonic acid.
7. the Orally taken emulsion of Pabuk former times profit cloth according to claim 1, wherein the acceptable acidic auxiliary material is tartaric acid.
8. Pabuk former times profit cloth Orally taken emulsion according to claim 1, wherein the sweetener is selected from sucrose, stevioside
Glycosides, saccharin sodium, aspartame, Sucralose or combination.
9. Pabuk former times profit cloth Orally taken emulsion according to claim 1, wherein the antioxidant is selected from vitamin E, fourth
Change hydroxy-methylbenzene, butylated hydroxy anisole or combination.
10. Pabuk former times profit cloth Orally taken emulsion according to claim 1, wherein the medicinal oil is selected from soybean oil, coconut
Oil, corn oil, oleic acid, linoleic acid, Glycerin, mixed triester with caprylic acid capric acid or combination.
11. Pabuk former times profit cloth Orally taken emulsion according to claim 1, wherein the medicinal emulsifier gathers selected from moon silicic acid
- 32 glyceride of ethylene glycol, Labraso, Tweens surfactant, gathers sad LABRAFIL M 1944CS
Ethylene oxide castor oil, Crodaret and polyethylene glycol 15 hydroxystearate or combination.
12. Pabuk former times profit cloth Orally taken emulsion according to claim 1, further includes medicinal organic solvent, selected from ethylene glycol, third
Glycol, isopropanol, Solutol HS15, ethylene glycol monomethyl ether and Liquid Macrogol~600 or its group
It closes.
13. Pabuk former times profit cloth Orally taken emulsion according to claim 1, further includes preservative, selected from benzoic acid, nipalgin
Ester, sorbic acid or combination.
14. the preparation method of the Orally taken emulsion such as claim 1-13 any one of them Pabuk former times profit cloth, it is characterised in that packet
Include following steps：
(1) prepare raw material according to aforementioned proportion；
(2) aqueous solution of acidic excipient is prepared；
(3) it is added in Pabuk former times profit cloth free alkali or its officinal salt in oxytropism auxiliary material aqueous solution, until dissolving is complete；
(4) sweetener, medicinal organic reagent and preservative are added in into more than aqueous solution, dissolving is complete；
(5) medicinal emulsifier is added in into medicinal oil, until dissolving is complete；
(6) Jiang Shui, oil two kinds of solution mixing by quickly stirring or ultrasound, obtain the emulsion of stable and uniform.
15. the Orally taken emulsion of Pabuk former times profit cloth as described in claim 1, dosage 10mg-200mg, preferably 50~
150mg。
16. the Orally taken emulsion of Pabuk former times profit cloth as described in claim 1 answering in the drug for treating breast cancer is prepared
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611152864.0A CN108210454A (en) | 2016-12-14 | 2016-12-14 | A kind of Orally taken emulsion of Pabuk former times profit cloth and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611152864.0A CN108210454A (en) | 2016-12-14 | 2016-12-14 | A kind of Orally taken emulsion of Pabuk former times profit cloth and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108210454A true CN108210454A (en) | 2018-06-29 |
Family
ID=62638546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611152864.0A Pending CN108210454A (en) | 2016-12-14 | 2016-12-14 | A kind of Orally taken emulsion of Pabuk former times profit cloth and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108210454A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113845520A (en) * | 2021-09-09 | 2021-12-28 | 安徽皓元药业有限公司 | Palbociclib orotate and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101066245A (en) * | 2007-05-25 | 2007-11-07 | 朱芳海 | Orally taken emulsion and its prepn |
| CN101502488A (en) * | 2009-03-13 | 2009-08-12 | 沈阳药科大学 | Teniposide emulsion and preparation method thereof |
| CN101780037A (en) * | 2010-02-03 | 2010-07-21 | 南昌大学 | Dipyridamole self-emulsifying medicament administration system and preparation method thereof |
| CN101912447A (en) * | 2010-07-30 | 2010-12-15 | 马宏达 | Rhizoma corydalis total alkaloids self-emulsifying drug delivery system and preparation method and application thereof |
| CN104825391A (en) * | 2015-04-21 | 2015-08-12 | 中国药科大学 | Pradaxa-containing microemulsion preparation |
| CN105816437A (en) * | 2016-03-29 | 2016-08-03 | 深圳市华力康生物医药有限公司 | Medicinal preparation of palbociclib and preparing method thereof |
| WO2016193860A1 (en) * | 2015-06-04 | 2016-12-08 | Pfizer Inc. | Solid dosage forms of palbociclib |
-
2016
- 2016-12-14 CN CN201611152864.0A patent/CN108210454A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101066245A (en) * | 2007-05-25 | 2007-11-07 | 朱芳海 | Orally taken emulsion and its prepn |
| CN101502488A (en) * | 2009-03-13 | 2009-08-12 | 沈阳药科大学 | Teniposide emulsion and preparation method thereof |
| CN101780037A (en) * | 2010-02-03 | 2010-07-21 | 南昌大学 | Dipyridamole self-emulsifying medicament administration system and preparation method thereof |
| CN101912447A (en) * | 2010-07-30 | 2010-12-15 | 马宏达 | Rhizoma corydalis total alkaloids self-emulsifying drug delivery system and preparation method and application thereof |
| CN104825391A (en) * | 2015-04-21 | 2015-08-12 | 中国药科大学 | Pradaxa-containing microemulsion preparation |
| WO2016193860A1 (en) * | 2015-06-04 | 2016-12-08 | Pfizer Inc. | Solid dosage forms of palbociclib |
| CN105816437A (en) * | 2016-03-29 | 2016-08-03 | 深圳市华力康生物医药有限公司 | Medicinal preparation of palbociclib and preparing method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113845520A (en) * | 2021-09-09 | 2021-12-28 | 安徽皓元药业有限公司 | Palbociclib orotate and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080038335A1 (en) | Method, formulation, and use thereof for improved oral absorption of pharmaceuticals or nutrients | |
| CN105294676B (en) | A kind of jamaicin double salt and its production and use | |
| CN102631405A (en) | Compound apigenin nanoemulsion antihypertensive drug | |
| CN1846712B (en) | Cinobufagin emulsion for injection and its preparation process | |
| CN1582159A (en) | Preparing material of flavanol wood lipid with increased solubility | |
| CN102796112B (en) | Prenylflavonoid compound and application thereof in preparation of pancrelipase inhibitor | |
| CN108210454A (en) | A kind of Orally taken emulsion of Pabuk former times profit cloth and preparation method thereof | |
| CN102058642B (en) | Ginseng saponin extract and preparation method thereof | |
| CN111643451B (en) | Honokiol self-emulsifying microemulsion preparation for injection and preparation method thereof | |
| CN102731276A (en) | Diterpene compound possessing antitumor activity, preparation method thereof and application thereof | |
| CN105142671B (en) | The composition of Cabazitaxel and Sulfobutylether beta-cyclodextrin | |
| CN101259100B (en) | Etoposide preparations and preparation thereof | |
| CN100462361C (en) | Formononetin-3'-sodium sulfonate, prunetin-3'-sodium sulfonate and their prepn process and medicinal use | |
| CN100502867C (en) | Preparation of sinomenine as antineoplastic medicament | |
| CN103110680A (en) | Preparation method of total phenolic acid of erigeron breviscapus | |
| CN104083348B (en) | Four kinds of kauran diterpene compounds are preparing the application in glycosidase inhibitor | |
| CN102784139B (en) | Pharmaceutical composition for treating diabetes associated with hyperlipemia and preparation method | |
| CN105796637A (en) | Anti-breast cancer traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN105963307A (en) | Applications of mogrol derivative monomer and composition thereof | |
| CN106063788A (en) | Phillyrin, phillyrin derivant, phillyrin are alleviated or/and the application in medicine or health product is vomitted in treatment in preparation with phillygenol compositions | |
| CN106474097A (en) | Anticarcinogen | |
| CN102552491A (en) | Dai-dai fruit total flavonoid self-microemulsion micro pill and preparation method thereof | |
| KR102470029B1 (en) | Pharmaceutical compositions for preventing or treating cholesterol gallstone comprising ursodeoxycholic acid(UDCA) and omega-3 and process for producing the same | |
| CN1315472C (en) | Motherwort dropping pill and its preparing method | |
| CN105125532A (en) | Medicament oxaliplatin composition for treating cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180629 |